Industry News
New NTRK-targeted therapy shows early promise against tumors with NTRK gene fusions
11/08/2015
The investigational anticancer therapeutic LOXO-101, which targets a family ofproteins called neurotrophic tyrosine kinase receptors (NTRKs), was safe, tolerable, and showedsigns of clinical...
IMMU-132, an anti-Trop-2 antibody-drug conjugate (ADC) was safe, tolerable,and yielded meaningful clinical activity in heavily pretreated patients with metastatic triplenegativebreast cancer...
Mutant-IDH1 inhibitor AG-120 shows early promise against solid tumors with IDH1 mutations
11/08/2015
The investigational anticancer therapeutic AG-120, which targets mutant IDH1protein, was well tolerated and showed signs of clinical activity in patients who had advancedsolid tumors positive...
Different approach needed for rare cancers
11/08/2015
Finding treatments for rare cancers requires novel approaches that don't need large numbers of patients for clinical trials, says respected cancer researcher Professor Ian Olver in an editorial...
Adding the investigational anticancer therapeutic tivantinib to standard erlotinibtreatment substantially increased progression-free survival for patients with advancednonsquamous non-small...
AZD9291 shows clinical activity in non-small cell lung cancer patients with leptomeningeal disease
11/07/2015
The epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)AZD9291 crossed the blood-brain barrier and showed clinical activity in heavily pretreated nonsmallcell lung cancer...
Treatment with the investigational pan-AKT inhibitor AZD5363 led to tumorregression in patients with a variety of types of solid tumors positive for the AKT1 E17K geneticmutation, according to...
For patients with colorectal cancer enrolled in a phase I clinical trial1, response tothe combination treatment being tested and disease progression were accurately tracked byquantifying levels...
300 oranges' worth of vitamin C impairs cancer cells
11/06/2015
The equivalent of 300 oranges' concentration of vitamin C impairs growth of KRAS- or BRAF-type colorectal cancer cells through a process of oxidization, a new study finds.
Loss of SMAD4 gene in certain colorectal cancers is associated with poor prognosis
11/06/2015
Among colorectal cancers, loss of the gene SMAD4 was significantly morecommon in cancers arising in the hindgut (the left side of the colon to the rectum) than in cancersarising in the midgut...